Review supports Allo-HSCT for BCR-ABL(+) AML with TKI and chemotherapy

This publication is a case report and literature review focusing on the management of BCR-ABL(+) acute myeloid leukemia. The scope of the review encompasses the therapeutic strategy involving tyrosine kinase inhibitors in combination with chemotherapy, followed by allogeneic hematopoietic stem cell transplantation. The authors evaluate the current landscape of treatment options for this specific disease subtype.

The key argument synthesized by the authors is that allogeneic hematopoietic stem cell transplantation provides strong support as a therapeutic option for this subtype. However, the authors highlight significant limitations in the current evidence base. They observe that case reports on this AML subtype remain relatively scarce to date, which limits the robustness of the conclusions drawn from the available literature.

Furthermore, the review identifies a critical gap in the field: currently, there is no unified standard treatment regimen for this disease. Due to the scarcity of high-quality data and the lack of standardized protocols, the practice relevance is tempered by the need for caution. Clinicians should interpret these findings within the context of the existing evidence gaps rather than viewing them as definitive guidelines for universal application.